DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,384,218 | +1.6% | 57,978 | -1.7% | 0.54% | +5.1% |
| Q2 2023 | $14,150,760 | -1.6% | 58,962 | +3.4% | 0.51% | -8.9% |
| Q1 2023 | $14,374,472 | -13.4% | 57,033 | -8.8% | 0.56% | -15.7% |
| Q4 2022 | $16,594,653 | +5.6% | 62,522 | +2.8% | 0.67% | -2.2% |
| Q3 2022 | $15,714,000 | +31.1% | 60,837 | +28.7% | 0.68% | +32.2% |
| Q2 2022 | $11,982,000 | -11.8% | 47,265 | +2.1% | 0.52% | 0.0% |
| Q1 2022 | $13,583,000 | -21.4% | 46,308 | -11.9% | 0.52% | -18.0% |
| Q4 2021 | $17,285,000 | +7.3% | 52,538 | -0.7% | 0.63% | -4.1% |
| Q3 2021 | $16,114,000 | +10.2% | 52,932 | -2.8% | 0.66% | +11.0% |
| Q2 2021 | $14,616,000 | +15.5% | 54,465 | -3.1% | 0.59% | +6.3% |
| Q1 2021 | $12,652,000 | -5.7% | 56,211 | -7.0% | 0.56% | -8.9% |
| Q4 2020 | $13,423,000 | +0.8% | 60,426 | -2.3% | 0.61% | -5.9% |
| Q3 2020 | $13,315,000 | +21.5% | 61,836 | -0.3% | 0.65% | +9.8% |
| Q2 2020 | $10,962,000 | +34.4% | 61,995 | +5.2% | 0.59% | +12.6% |
| Q1 2020 | $8,158,000 | -7.8% | 58,938 | +2.3% | 0.52% | +8.0% |
| Q4 2019 | $8,845,000 | +0.2% | 57,631 | -5.7% | 0.48% | -3.4% |
| Q3 2019 | $8,824,000 | +1.4% | 61,098 | +0.3% | 0.50% | -0.2% |
| Q2 2019 | $8,702,000 | +7.3% | 60,888 | -0.9% | 0.50% | +2.0% |
| Q1 2019 | $8,108,000 | +26.0% | 61,418 | -1.6% | 0.49% | +10.5% |
| Q4 2018 | $6,433,000 | -6.3% | 62,387 | -1.3% | 0.45% | +10.1% |
| Q3 2018 | $6,865,000 | +8.4% | 63,182 | -1.6% | 0.40% | -5.4% |
| Q2 2018 | $6,334,000 | -0.5% | 64,190 | -1.2% | 0.43% | -1.6% |
| Q1 2018 | $6,363,000 | +3.3% | 64,984 | -2.0% | 0.44% | +5.6% |
| Q4 2017 | $6,157,000 | +8.8% | 66,338 | +0.6% | 0.41% | +2.5% |
| Q3 2017 | $5,659,000 | -8.9% | 65,971 | -10.4% | 0.40% | -9.9% |
| Q2 2017 | $6,211,000 | -8.7% | 73,595 | -7.5% | 0.45% | -12.0% |
| Q1 2017 | $6,801,000 | +9.4% | 79,520 | -0.4% | 0.51% | +3.5% |
| Q4 2016 | $6,217,000 | +0.8% | 79,870 | +1.5% | 0.49% | -2.6% |
| Q3 2016 | $6,167,000 | -22.4% | 78,672 | +0.0% | 0.50% | -22.3% |
| Q2 2016 | $7,945,000 | +5.6% | 78,667 | -0.8% | 0.65% | -42.7% |
| Q1 2016 | $7,524,000 | -0.6% | 79,317 | -2.7% | 1.13% | +4.1% |
| Q4 2015 | $7,570,000 | +2.3% | 81,506 | -6.2% | 1.09% | +3.6% |
| Q3 2015 | $7,402,000 | -4.4% | 86,872 | -4.0% | 1.05% | +5.2% |
| Q2 2015 | $7,743,000 | +2.3% | 90,461 | +1.5% | 1.00% | +5.2% |
| Q1 2015 | $7,567,000 | -0.1% | 89,131 | +0.9% | 0.95% | -0.5% |
| Q4 2014 | $7,573,000 | +12.0% | 88,356 | -0.7% | 0.95% | +7.3% |
| Q3 2014 | $6,762,000 | +0.2% | 88,994 | +3.8% | 0.89% | -0.4% |
| Q2 2014 | $6,751,000 | +13.1% | 85,750 | +7.7% | 0.89% | +11.5% |
| Q1 2014 | $5,971,000 | +12.9% | 79,613 | +16.3% | 0.80% | +10.2% |
| Q4 2013 | $5,287,000 | +20.5% | 68,484 | +8.2% | 0.72% | +10.0% |
| Q3 2013 | $4,386,000 | +10.8% | 63,266 | +1.2% | 0.66% | +7.9% |
| Q2 2013 | $3,957,000 | – | 62,506 | – | 0.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |